NCT05404945View on ClinicalTrials.gov

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

October 3, 2027

Study Completion Date

October 3, 2027

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab 400 mg IV

DRUG

Doxorubicin

Doxorubicin 25mg/m2 IV

DRUG

Vinblastine

Vinblastine 6mg/m2 IV

DRUG

Dacarbazine

Dacarbazine 375mg/m2 IV

DRUG

Brentuximab vedotin

Brentuximab vedotin 1.8 mg/kg IV

Trial Locations (3)

19104

NOT_YET_RECRUITING

University of Pennsylvania, Philadelphia

22911

RECRUITING

University of Virginia, Charlottesville

08902-2681

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Virginia

OTHER